HIV type-1 (HIV-1) infected patients are routinely treated with combinations of three or four drugs (highly active antiretroviral therapy, HAART). Etravirine (ETR, TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretrovirals (ARV) for treatmentexperienced patients of at least 6 years of age. A population PK model was previously developed using data from two phase III trials and pediatric trials.
Despite the large variability in the ETR PK, only limited covariates could be identified to explain this variability. More recent data for ETR have become available, looking at specific concomitant ARV and polymorphisms of CYP2C9 and CYP2C19.